hotspot -WSS

hotspot

author：comprehensive 2025-09-07 17:29:10 - browse：2

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

knowledge

hotspot

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

The drug industry has found itself all alone in Washington

AI gets buy

The CDC's new social media misinformation war

Amylyx ALS drug failure raises questions and concerns

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

hotspot

focus

Alkermes shareholders re

RSV shot was 90% effective at preventing hospitalizations in kids

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A single Democrat is willing to weaken Medicare negotiation power

Hepatitis C has a cure — but many Americans still lack access to it

Gene therapy for Afghan refugees’ infant will be fully covered

In Memoriam: Notable people who died in 2023

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Jerome Adams on the need for new antivirals for Covid

CDC marks new Covid

leisure time

What’s missing from the debate over nursing home staff minimums

IVF, abortion rights issues kick off Biden’s State of the Union

The CDC's new social media misinformation war

A protest over insulin prices is seen as a fight for life

Why Novartis is going to walk from its acquisition of MorphoSys

Devoted Health’s losses in Medicare Advantage persist

knowledge

focus

hotspot

leisure time